
Annual report 2025
added 03-31-2026
ENDRA Life Sciences Net Debt 2011-2026 | NDRA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt ENDRA Life Sciences
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -270 K | -2.65 M | -4.37 M | -8.78 M | -6.54 M | -5.47 M | -6.47 M | -5.6 M | 805 K | -19.1 K | -156 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 805 K | -8.78 M | -3.59 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 15.85 | -2.49 % | $ 171 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 115.06 | -0.29 % | $ 35 B | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
1.19 M | $ 1.13 | -2.59 % | $ 6.15 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 16.05 | -3.83 % | $ 855 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 23.13 | -1.28 % | $ 642 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 2.3 | - | $ 10.2 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 175.65 | 0.06 % | $ 8.71 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Danaher Corporation
DHR
|
14 B | $ 189.61 | -1.7 % | $ 135 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 493.53 | -1.59 % | $ 14.2 B | ||
|
Illumina
ILMN
|
-494 M | $ 120.93 | -2.22 % | $ 19.2 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 14.43 | -3.93 % | $ 436 M | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.35 | -2.03 % | $ 403 M | ||
|
NeoGenomics
NEO
|
187 M | $ 7.69 | -3.17 % | $ 985 M | ||
|
Guardant Health
GH
|
1.15 B | $ 78.6 | -9.83 % | $ 9.85 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.69 | -1.82 % | $ 87.3 K | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.13 | -0.9 % | $ 4.89 M | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 28.31 | 0.62 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 106.81 | 0.1 % | $ 8.81 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 260.93 | -4.51 % | $ 21.7 B | ||
|
Natera
NTRA
|
-177 M | $ 193.03 | -4.91 % | $ 19 B | ||
|
Celcuity
CELC
|
-28.1 M | $ 117.14 | -6.02 % | $ 5.48 B | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 80.59 | -1.03 % | $ 5.44 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 191.51 | -3.19 % | $ 21.3 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.42 | -6.13 % | $ 2.04 B | ||
|
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | ||
|
National Research Corporation
NRC
|
71.3 M | $ 16.48 | -3.34 % | $ 369 M |